Genprex shares jump 27.75% intraday after signing exclusive license agreement with NYU Langone for mesothelioma treatment.

Genprex (GNPX) surged 27.75% intraday following two key developments: (1) signing an exclusive license agreement with NYU Langone Health to develop therapies for mesothelioma on April 28, and (2) being selected to present its Acclaim-3 clinical trial design for Reqorsa® gene therapy in small cell lung cancer at the 2025 ASCO Annual Meeting on April 24. These announcements, coupled with prior positive preclinical data on Reqorsa® for lung cancer and diabetes from March 2025, reinforced investor confidence in the company’s pipeline advancements. The strategic partnership with NYU and high-profile trial visibility at ASCO signaled progress in expanding therapeutic applications and validating its gene therapy platform, driving immediate upward momentum.